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Background: Known antiretroviral restriction factors are encoded by genes that are under positive selection pressure,
induced during HIV-1 infection, up-regulated by interferons, and/or interact with viral proteins. To identify
potential novel restriction factors, we performed genome-wide scans for human genes sharing molecular and
evolutionary signatures of known restriction factors and tested the anti-HIV-1 activity of the most promising candidates.
Results: Our analyses identified 30 human genes that share characteristics of known restriction factors. Functional
analyses of 27 of these candidates showed that over-expression of a strikingly high proportion of them significantly
inhibited HIV-1 without causing cytotoxic effects. Five factors (APOL1, APOL6, CD164, TNFRSF10A, TNFRSF10D) suppressed
infectious HIV-1 production in transfected 293T cells by >90% and six additional candidates (FCGR3A, CD3E, OAS1,
GBP5, SPN, IFI16) achieved this when the virus was lacking intact accessory vpr, vpu and nef genes. Unexpectedly,
over-expression of two factors (IL1A, SP110) significantly increased infectious HIV-1 production. Mechanistic studies
suggest that the newly identified potential restriction factors act at different steps of the viral replication cycle,
including proviral transcription and production of viral proteins. Finally, we confirmed that mRNA expression of
most of these candidate restriction factors in primary CD4+ T cells is significantly increased by type I interferons.
Conclusions: A limited number of human genes share multiple characteristics of genes encoding for known
restriction factors. Most of them display anti-retroviral activity in transient transfection assays and are expressed in
primary CD4+ T cells.
Keywords: Host restrictions factors, Evolutionary genomics, HIV-1Background
Antiretroviral innate defense genes such as TRIM5α,
APOBEC3G, BST2/Tetherin, and SAMHD1 exhibit char-
acteristic evolutionary signatures of powerful selective
pressures reflecting a long-standing evolutionary arms
race between the host and viral pathogens [1]. A second
common characteristic of these genes is that they are
interferon-inducible and differentially expressed during
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unless otherwise stated.directly with viral proteins, either to exert their antiviral
activity or because they are targeted by viral antagonists
[4-6]. Thus, evolutionary and molecular characteristics,
such as positive selection in primate genomes, differential
expression during infection, and interaction with viral
components might constitute a distinct signature of genes
endowed with antiviral activity.
We leveraged the availability of complete genome se-
quences of several primate species (human, chimpanzee,
gorilla, orangutan, macaque, marmoset, tarsier, bush-
baby, and mouse lemur) to perform a genome-wide
screen for genes carrying the signatures of known host
restriction factors. To address this, we examined which
human genes that are differentially expressed duringl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
McLaren et al. Retrovirology  (2015) 12:41 Page 2 of 15HIV-1 infection, and/or encode host factors interacting
with viral proteins have also been subject to diversifying
selection during primate evolution. Candidates carrying
the most promising combined signatures were exam-
ined for their effects on different steps of the HIV-1
replication cycle. We emphasized the confirmation of
the IFN-induced nature of the candidates, their significant
expression in HIV-1 target cells, the efficient reduction of
infectious virus production in the over-expression screen,
and a particular emphasis on genes that affected the infec-
tiousness of HIV-1 more severely than viral gene expres-
sion and/or showed some specificity for the LTR promoter.
The combination of bioinformatics criteria with a broad
functional screen allowed bringing a large data set of genes
to a manageable list of candidates for further analyses. Our
results demonstrate that over-expression of a surprisingly
high proportion of these genes inhibits infectious HIV-1
production and suggest that the viral accessory proteins
Vpr, Vpu and/or Nef may diminish the antiviral effect of
some of these cellular factors.
Results
Genes that are induced during HIV-1 infection have a
distinct evolutionary profile
To examine the contribution of differences in cellular
gene expression to viral control, we have previously gen-
erated transcriptome data from CD4+ T cells of
untreated HIV-1 infected individuals with different viral
loads [3,7]. Additional gene expression data were
obtained from published sources on lymph nodes during
HIV-1 infection [8]. We also assessed the evidence for
evolutionary pressure on all genes by comparing human
gene sequences to those of eight additional simian and
prosimian species (see methods) and calculated a gene-
wide ratio of non-synonymous (dN) to synonymous (dS)
substitutions (gene dN/dS). We found that genes whose
expression is positively correlated to viral load in CD4+
T cells (n = 180) or induced in lymph nodes (n = 360) of
HIV-1 infected persons had higher dN/dS values than
the genome-wide median for primates (CD4+ T cell gene
set, dN/dS 0.25 vs 0.18, p <10−5, and lymph node gene
set dN/dS 0.28 vs 0.18, p <10−5) (Figure 1A). Genes with
dN/dS values inflated above the genome-wide reference
could either be evolving under more neutral selection,
or could have within them certain codons evolving
under positive selection that bring up the gene-wide dN/
dS value. Across these expression datasets, 30 genes up-
regulated during HIV-1 infection were under positive
selection (dN/dS >1).
We next examined whether such an evolutionary pattern
is also observed in other human infections [9-12]. Com-
pared with the dN/dS genome median of 0.18, genes that
are differentially expressed during Dengue virus infec-
tion (n = 158), salmonellosis (n = 205), or activetuberculosis (n = 251) generally had higher dN/dS
values (Dengue, 0.22, p = 0.02; salmonellosis 0.20, p =
0.04; and tuberculosis 0.23, p = 2×10−5) (Figure 1B). A
similar pattern was identified for three curated sets of in-
nate immunity genes (http://www.innatedb.ca; n = 1714)
that displayed a statistically significant shift to high dN/dS
values (all p < 2×10−4) (Figure 1C). Altogether, these re-
sults demonstrate that genes associated with infection and
immune response show distinctly higher dN/dS values in
primates. Although a higher dN/dS value could be indi-
cative of relaxed constraint rather than positive selec-
tion [13], immune-related genes have consistently been
observed to evolve with higher dN/dS values and show
evidence for codon-specific positive selection [14].
We then extended the analysis to genes described in
the NCBI HIV-1 protein interaction database (n = 1251)
and in the global landscape of HIV-human protein com-
plexes (n = 350) [15]. These sets of genes had a significantly
lower median dN/dS than the genome-wide median for
primates (0.14 and 0.13 vs 0.18, respectively, both p <10−5,
Figure 1C). The shift to conservation is comparable
to that of other characteristically conserved genes
such as those of the OMIM Mendelian disease data-
base (n = 1289) (Figure 1C). This most likely reflects
the fact that HIV has to interact with numerous well-
conserved cellular factors (“HIV dependency factors”)
to complete its replication cycle. Although the two
HIV interaction datasets were more conserved, 35
genes had dN/dS >1. As indicated below, some genes
under positive selection were common to both the
expression and the interaction datasets.
Selection of 30 candidate restriction factors for
experimental validation
Our initial evolutionary scan identified 841 genes (out of
a total of 21,389) with a dN/dS ratio > 1 (Figure 2A). We
next evaluated in detail the functional profile of this sub-
set by assessing their level of upregulation during HIV-1
infection in vivo, and/or evidence for interaction with
viral proteins (see Methods) resulting in an initial short-
list of 57 genes (Additional file 1: Table S1). To confi-
dently assess the genes' evolutionary signatures, we used
the codon-level analysis package (codeml) in the Phylo-
genetic Analysis Using Maximum Likelihood (PAML
[16]) software on curated multiple alignments of primate
genes (see Methods). This method averages per-codon
dN/dS estimates across a gene and assesses the evidence
for codon-level selection using maximum likelihood esti-
mation. Of the initial 57 candidates, we selected 30 genes
for functional analyses based on significant evidence of
positive selection at one or more amino acid sites
(Additional file 1: Table S1). Eleven of these 30 candidate
genes were chosen because they are upregulated during
HIV-1 infection, 14 have been shown to interact with viral















































Figure 1 Evolutionary pattern of the protein coding genome in primates. Probability density curves of continuous dN/dS values for genes (A)
upregulated in CD4+ T cells and in lymph nodes during infection with HIV-1 in vivo in humans, (B) genes differentially regulated during infection of
humans with other pathogens and (C) datasets of human innate immunity genes including: an innate immune specific set (Innate DB), genes curated
by the Immunogenetic Related Information Source (IRIS) and a manually curated list of immune genes (Immunome), the NCBI HIV interaction
database (Interaction DB), the global landscape of HIV-human protein complexes from Jaeger et al. (Jaeger) [15], and of genes associated with
Mendelian disorders in OMIM. The kernel smoothed density estimates (density) of dN/dS values for sets of genes is plotted. The height of the
curves is relative to the number of genes with the observed dN/dS values. The genome-wide background dN/dS values for 17,755 genes is
shown in grey. Statistically significant differences (Kolmogorov-Smirnov statistics p ≤ 0.05) were observed for distributions towards greater dN/
dS values for genes differentially expressed in CD4+ T cells and lymph nodes during HIV-1 infection, in infection with Dengue virus, Salmonella
typhic and tuberculosis, and for distributions towards smaller dN/dS values for genes involved in HIV-1-human interaction datasets and in the
catalog of Mendelian disorders.
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proof-of-principle, TRIM5α and APOBEC3G were iden-
tified in the screen. Consistent with previous reports
[17,18], BST2 and SAMHD1 reached dN/dS ratios of
0.78 and 0.49, respectively; therefore, they were not
shortlisted on the basis of global dN/dS ratios, although
they displayed codon-specific positive selection. To also
consider factors displaying only codon-specific positive
selection, we additionally performed a second screen
and ranking approach that are described below.
Cell based assays for assessment of restriction
To examine possible antiviral effects of the candidate
genes, we developed cell-based assays to determine their
impact on HIV-1 gene expression, virus production and
viral infectivity. A total of 27 candidate genes Additional
file 1: Table S1 were cloned into a bi-cistronic vector coex-
pressing the gene of interest and the blue fluorescent pro-
tein (BFP) via an internal ribosome entry site (IRES)
(Figure 2B). Three of the 30 genes (PARP9, SGOL2,
SPAG5) could not be PCR amplified and cloned from
cDNA of primary blood cells. 293T cells were cotrans-
fected with the gene expression constructs and HIV-1
NL4-3-based proviral IRES/eGFP constructs. The latter ex-
press Nef and the enhanced version of the green fluores-
cent protein (eGFP) from the same viral RNAs [19]. Thus,
the green fluorescence intensity is an indicator of early viral
gene expression. To identify possible antagonistic effects ofthe viral Vpr, Vpu and Nef proteins on the candidate
gene products, we screened them for inhibition of a
wild-type (wt) NL4-3-based HIV-1 construct and an
otherwise isogenic derivate thereof (named Δ3) containing
defects in these three accessory genes (Figure 2B). The ef-
fect of candidate genes on early LTR-driven gene ex-
pression was quantified by fluorescence-activated cell
sorting (FACS) at 36 to 48 hours post-transfection
(Figure 2C). To monitor the expression of late viral
gene products, virus release and infectivity of progeny
virions, we assessed the quantity of cell-associated
and cell-free p24 capsid antigen and the infectivity of
the viral supernatants (Figure 2C). The FACS-based
assay allowed us to readily determine the percentage of
cells expressing the proviral HIV-1 genome and the
cellular candidate genes both alone and in combination
(Figure 2D). Importantly, none of the 27 candidate genes
caused significant cytotoxic effects or reduced the meta-
bolic activity of the cells under the experimental condi-
tions used to determine their antiviral activity (Additional
file 2: Figure S1).
A high proportion of candidate genes display anti-HIV-1
activity
We found that most candidate genes reduced the fre-
quency of HIV-1-expressing (eGFP+) cells, on average
by about 30% (Figure 3A, Additional file 2: Figure S2
and Additional file 1: Table S1). Expression of four
Figure 2 Experimental setup of the screen and the different measurements involved. (A) In orthogonal screens, 841 human genes were identified to
be under positive selection, of which only 30 were retained as candidates (11 were upregulated during HIV-1 infection, 14 reported to interact with
viral proteins, and 5 fulfilled both criteria). (B) Schematic presentation of the bi-cistronic constructs coexpressing the gene candidate together with the
blue fluorescent protein (BFP) under the control of a CMV promoter and the HIV-1 NL4-3-based IRES-eGFP proviral reporter construct. The position of
premature stop codons in the vpr, vpu and nef genes of the Δ3 derivative are indicated by stars. (C) Overview of the experimental outline to determine
the effect of cotransfected gene candidates on early viral gene expression (detection of eGFP by FACS) and late viral gene expression (cell-associated
p24 antigen ELISA), virion release (cell-free p24 antigen ELISA) and viral infectivity (TZM-bl reporter assay). (D) Examples of primary FACS data. 293T cells
were transfected with the indicated proviral constructs and expression vectors and analyzed by flow cytometry 48 h later.
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TNFRSF10D) achieved more than 50% inhibition,
whereas two genes (IFI44L, SP110) slightly increased
the frequency of eGFP+ cells. The effects of the candi-
date genes on wt and Δ3 HIV-1 constructs in the
FACS-based assay correlated significantly (R2 = 0.93; p
< 0.0001) (Additional file 2: Figure S3A). This was ex-
pected because defects in the vpr, vpu and nef genes
should not affect early viral gene expression upon
transfection of proviral HIV-1 constructs.
The FACS-based assay also provides an indication for
the strength of viral gene expression based on the eGFPmean fluorescence intensity (MFI) since Nef and eGFP
are expressed from the same double-spliced bi-cistronic
RNA. We found that most candidate genes suppressed
LTR-dependent eGFP expression (Figure 3B) and ob-
served a significant but imperfect correlation (R2 = 0.57,
p < 0.0001) between the effects of the candidate genes on
the percentages of eGFP+ cells and the MFIs of eGFP
(Additional file 2: Figure S3B). In addition to the four fac-
tors mentioned above (APOL1, APOL3, APOL6 and
TNFRSF10D), two additional candidates (OAS1 and IFI16)
reduced the MFI of eGFP by more than 50% (Additional
file 2: Figure S2 and Additional file 1: Table S1).
FA B C D E
Figure 3 Identification of candidate genes that affect HIV-1 replication. (A) HIV-1-expressing (eGFP+) cells and (B) mean eGFP fluorescence inten-
sities in the presence of over-expressed gene candidates at 48 h post transfection. (C) Levels of infectious HIV-1 determined by infection of TZM-
bl indicator cells with the culture supernatant of transfected 293T cells. (D, E) cell-free (CF) and cell-associated (CA) p24 antigen levels from 293T
cell cultures cotransfected with wt or vpr, vpu and nef defective (Δ3) HIV-1 constructs and gene candidate expression vectors. All panels provide
values relative to those measured in 293T cultures cotransfected with the wt and Δ3 proviral HIV-1 constructs and the control vector expressing
BFP only (100%). Each symbol represents the average value obtained from three independent experiments for each of the gene candidates ana-
lyzed. All candidates that reduced the values <50% in the FACS-based and <10% in the remaining assays are highlighted in green and selected
genes that showed enhancing effect are indicated in red. (F) Unsupervised clustering of the different readouts allows inspection of similar activ-
ities across genes, and of the correlation between the various steps, for wt and Δ3 HIV-1.
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intracellular p24 by 49.1% (Figure 3C) and cell-free p24
production by 48.2% (Figure 3D) for the wt virus. All can-
didate genes that reduced p24 antigen expression and pro-
duction in cells infected with the wt HIV-1 construct also
inhibited the Δ3 virus but the effects were often stronger,
i.e. 72.5% (p = 0.028) reduction of cell-associated and
63.8% reduction of cell-free p24 production (Figures 3C
and 3D). A total of eight cellular factors (APOL1, APOL6,
TNFRSF10A, TNFRSF10D, IFI16, CD164, FCGR3A and
TRIM5α) caused >90% reduction of p24 release by the Δ3
virus (Additional file 2: Figure S2). We found a significantcorrelation between the quantities of cell-free and cell-
associated p24 antigen (R2 = 0.62 p < 0.0001) (Additional
file 2: Figure S3) and none of the 27 factors analyzed spe-
cifically suppressed virion assembly and/or release in the
transient transfection assay.
Altogether, over-expression of more than half (15 of
27) of the candidate genes reduced the production of in-
fectious wt HIV-1 by more than 75% and five factors
(APOL1, APOL6, TNFRSF10A, TNFRSF10D and CD164)
achieved >90% inhibition (Figure 3E, Additional file 2:
Figure S2 and Additional file 1: Table S1). All candidate
factors that suppressed the production of infectious wt
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file 2: Figure S3A). However, the inhibitory effects on
the Δ3 HIV-1 mutant were frequently even more pro-
nounced. In addition to the candidates listed above, six
additional cellular genes (OAS1, CD3E, GBP5, FCGR3A,
IFI16, and SPN) achieved >90% reduction of infectious
HIV-1 production if the virus was lacking intact vpr, vpu
and nef genes (Figure 3E, Additional file 2: Figure S2
and Additional file 1: Table S1). Two factors (IL1A and
SP110) enhanced the production of infectious HIV-1.
The enhancing effect was particularly pronounced for
the Δ3 HIV-1 construct (Figure 3E, Additional file 2:
Figure S2 and Additional file 1: Table S1). Altogether,
the levels of viral infectivity and cell-free p24 correlated
well (R2 = 0.66; p < 0.0001) although the effects on the
former were frequently more pronounced (Additional
file 2: Figure S3B). Some factors, such as GBP5 and SPN
reduced virion infectivity more severely (16.4% and
23.9%) than the release of p24 antigen (59.9% and
132.5%) (Figure 3F, Additional file 2: Figure S2 and
Additional file 1: Table S1) and may thus impair the in-
fectiousness of progeny virions.
To obtain first insights into the possible mechanisms
underlying the inhibitory effects, we examined whether
the reduced levels of eGFP+ (HIV-1-expressing) cells
correlate with the levels of infectious virus production
(Figure 3F). We found a significant but imperfect correl-
ation (R2 = 0.23; p = 0.0094) (Additional file 2: Figure
S3B) suggesting that reduction of viral gene expression
or translation is important but not the only inhibitory
mechanisms. For example, the TNFRSF10 genes reduced
eGFP expression in the FACS-based assay substantially
less effectively than APOL1, APOL3 and APOL6 but
achieved a similar reduction in infectious virus production
(Figure 3F, Additional file 2: Figure S2 and Additional file
1: Table S1).
Candidate restriction factors inhibit HIV-1 in a
dose-dependent manner
To further verify the antiretroviral activities, we next
measured infectious virus yields from 293 T cells after
cotransfection with fixed quantities of wt or Δ3 HIV-1
NL4-3 proviral vectors and increasing doses of plasmids
expressing 13 selected candidate genes. These titration
experiments confirmed that APOL1, APOL6, TNFRSF10A,
TNFRSF10D, CD164, OAS1, CD3E and FCGR3A inhibit
HIV-1 in a dose-dependent manner (Figure 4). The titra-
tion analyses also showed that some genes (APOL1,
APOL6, CD164 and CD3E) reduced the yield of infectious
wt HIV-1 slightly less efficiently than of the Δ3 virus.
Interestingly, FAS generally increased infectious HIV-1
production at low expression levels but significantly
reduced it at the highest dose of expression plasmids
(Figure 4). We also verified that SP110 and IL1Aincreased the infectious virus yield. Strikingly, IL1A
increased infectious virus yield by up to 3.5-fold for the
wt and even up to 7-fold for the Δ3 construct. Finally,
we examined the effects of the interferon-induced IFI44
and IFI44L. Notably, the latter reduced infectious HIV-
1 yield more efficiently (Figure 4) although both genes
share a significant degree of sequence homology.
Altogether, the titration experiments confirmed that
many of the newly identified candidate restriction
factors suppress infectious HIV-1 production in transi-
ently transfected 293T cells.
A high proportion of candidates affect the activity of viral
promoters
The FACS-based assays suggested that some of the can-
didate factors may reduce the transcription of viral
genes. To examine the effect of the candidate factors on
HIV-1 promoter activity, we cotransfected 293T cells
with a firefly luciferase reporter vector controlled by the
HIV-1 LTR, plasmids coexpressing the candidate genes
and BFP, and a construct expressing the NL4-3 Tat pro-
tein. For comparison, we also analyzed the effects on the
herpes simplex virus thymidine kinase (HSV-TK) and
cytomegalovirus immediate early (CMV-IE) promoters.
Many candidate factors, particularly APOL family mem-
bers and FCGR3A encoding the low affinity immuno-
globulin gamma Fc region receptor III-A, efficiently
suppressed HIV-1 LTR activity (Figure 5). However, the
effects were not specific for HIV-1 since these candidate
factors also inhibited the activity of the CMV-IE and
HSV-TK promoters. Perhaps more notably, several candi-
date genes, e.g. CD1A, CD3E, GBP5 and SPN had little if
any effect on viral LTR activity (Figure 5) but still effi-
ciently prevented the production of infectious HIV-1
(Additional file 2: Figure S2). Thus, the results confirmed
that reduced viral gene expression is an important but not
the only inhibitory mechanism.
A high proportion of candidate genes are interferon-
inducible in CD4+ T cells
The genome-wide screen used gene expression data
from in vivo studies in HIV-positive individuals where
gene expression was correlated to patient viral load
[3,7]. To better dissect the general agreement between
in vivo data with actual interferon inducibility, we
assessed the response of primary CD4+ T cells from
healthy donors to stimulation with interferon alpha,
interferon gamma and to cell activation via the T cell
receptor (TCR). The analysis identified a general agree-
ment between in vivo data and interferon alpha gene
induction, with the majority of the genes being strongly
up-regulated by stimulation (in healthy donors) and by
viral replication in HIV+ patients (Figure 6). These data
confirm that the in vivo response to HIV infection is
Figure 4 Titration of the effects of the gene candidates on infectious HIV-1 production. Virus release from 293T cells following transfection with 5 μg
of wt or Δ3 proviral NL4-3 constructs and varying amounts of plasmids expressing the indicated candidate genes. The total quantity of transfected
DNA was adjusted to 7.5 μg with empty vector. Infectious virus yield was determined by infection of TZM-bl indicator cells and is shown as percentage
of that detected in the absence of candidate gene expression. Values represent averages (±SD) derived from triplicate infections and the results were
confirmed in an independent experiment.
Figure 5 Effect of candidate gene expression on viral promoter activity. Effect of the indicated candidates on the activity of the HIV-1 LTR in the
presence of Tat and the CMV-IE and HSV-TK promoters. All data were normalized to the BFP only control construct (100%) and represent average
values (±SEM) derived from three transfections.
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drivers of immune activation, as exemplified here by
TCR stimulation, share parts of the signature. Thus,
many of the candidate genes identified in the present
study are true interferon-stimulated genes (ISGs) as
shown by in vivo and in vitro data and expressed in the
main target cells of HIV-1 in infected humans.
Relaxed screening approach ranks genes with potential
antiviral activity
The first screening imposed a hard threshold for inclu-
sion (dN/dS > 1) to identify genes under (global) positive
selection pressure. Use of this global gene metric is a
useful link to previous literature; however, tools such asFigure 6 Heat map of expression after stimulation of known HIV-1 restriction
left, CD4+ T cells from healthy donors were left unstimulated or stimulated w
(blue), and factors identified in the screen (black) were clustered using compl
correlation between gene expression in CD4+ T cells of HIV infected donors w
Positive R(VL) values (yellow) indicate an increased gene expression correlatesPAML that assess local signatures of selective pressure
and have built-in statistics are becoming a preferred
approach. In particular, genes of some known restriction
factors (e.g. BST2 and SAMHD1) just show signatures of
codon-specific (local) instead of global positive section
pressure. Thus, we explored a second genome-wide
approach to rank genes using several metrics based on
characteristics of innate immunity genes [20]. We ini-
tially considered eight parameters associated with innate
immunity genes: dN/dS value, codon-specific positive
selection (PAML), measurements of cross species adap-
tive evolution, burden of synonymous, missense and
non-sense variation, intolerance to functional variation
and number of paralogs, as well as the in vivo genefactors and gene candidates through the screening approach. On the
ith IFNα, IFNγ or αCD3/CD28. Expression levels of known restriction factors
ete hierarchical clustering. For comparison, the right panel depicts the
ith setpoint viral load (R(VL)). Correlation values were taken from [3].
with an increase in patient viral load (log10 RNA copies/ml).
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model using the set of known HIV restriction factors
(APOBEC3G, BST2/Tetherin, MX2, SAMHD1 and
TRIM5α). Gene parameters were iteratively included/ex-
cluded, and the final set of parameters was selected such
that the sum of the ranks across the known genes was
minimized (see Methods). We present in Additional file
3: Table S2 the top 200 ranked genes. This is a resource
that avoids the strict cutoff criteria of dN/dS >1 to accom-
modate a more extensive set of gene candidates. Known
restriction factors APOBEC3G, TRIM5α, MX2, SAMHD1
and BST2 were ranked 2, 5, 125, 277 and 379 among
15,052 protein-coding genes respectively in the final
model. Overall, 20 of the 30 candidates identified in the
initial screen also ranked above the 95 percentile for the
genome in the second approach, and all but one
(TNFRSF10D) ranked above the 75 percentile.
Discussion
In the present study, we utilized features of known anti-
viral host restriction factors [21], such as evolutionary
signatures of positive selection, expression during HIV
infection, and interaction with viral proteins, to identify
novel cellular factors that inhibit HIV-1. Initially, we per-
formed a canonical genome-wide screen revealing that
only a small proportion of the genome (841 of 21389
genes; 3.9%) shows evidence for positive selection in pri-
mates (dN/dS > 1). Next, we examined which of these
genes are significantly upregulated during HIV-1 infec-
tion in vivo and/or encode for cellular factors known to
interact with HIV-1 proteins. Based on these selection
criteria 30 candidate genes were selected for closer
examination and a strikingly high proportion of them
suppressed infectious HIV-1 production in transfected
293T cells. To consider the fact that known restriction
factors, such as APOBEC3G, BST2 and SAMHD1, show
site-specific rather than global evidence for positive se-
lection, we conducted a second screen with more flex-
ible modeling on features of known HIV restriction
factors to rank genes without imposing strict thresholds
for calling a candidate. All five known restriction factors
(APOBEC3G, TRIM5α, MX2, SAMHD1 and BST2)
ranked within the top 2.5% of all protein-coding genes
examined (average 1.0%). The analysis extends previous
work from our group [17] and work of Meyerson et al.
[22] that searched for signatures of positive selection
among previously described HIV host factor genes. The
current genome-wide analyses allowed identification of
additional genes sharing characteristics of known restric-
tion factors, a useful basis for the identification of novel
intrinsic antiretroviral cellular factors.
To evaluate possible antiviral effects of the selected
genes, we determined their impact on HIV-1 gene ex-
pression, virus production and viral infectivity. A set of27 genes encoding cellular proteins not previously impli-
cated as HIV-1 restriction factors were amplified from
primary human blood cells and cloned into a bi-
cistronic vector coexpressing the gene candidate BFP.
Over-expression of a striking proportion of candidate
genes (16 of 27; 59%) reduced the production of infec-
tious wt HIV-1 particles by more than 75% without
causing cytotoxic effects and this number was even
higher in the absence of intact vpr, vpu and nef genes
(20 of 27; 74%). For example, genes of the apolipoprotein
L gene family (APOL1, APOL3, APOL6) were generally
very potent inhibitors. All members of this gene family
have rapidly evolved in primates [23], and APOL1 has
been shown to confer immunity to Trypanosoma brucei
that can be countered by a trypanosome-encoded antag-
onist [24]. Members of the TNF-receptor superfamily
(TNFRSF10A and 10D) were also powerful inhibitors.
Notably, TNFRSF10A was also identified as one of the
most potent anti-HIV-1 factors among 380 type I
interferon-stimulated genes in a previous study [25]. An-
other potent inhibitor of HIV-1 was CD164 (also known
as endolyn) a cell adhesion molecule that interacts with
CXCR4 [26]. Furthermore, the high activity of OAS1 is
noteworthy because this interferon-induced factor is
known to generate 2',5'-oligoadenylates which activate
RNase L thus causing viral RNA degradation and inhib-
ition of viral replication [27]. Notably, OAS1 affected the
percentage of HIV-1 infected (eGFP+) cells less severely
than the mean fluorescence intensity of eGFP expres-
sion, which would be expected in the case of RNase L
mediated viral RNA degradation. A similar phenotype
was observed for IFI16, which is involved in transcrip-
tional regulation and plays a role in the sensing of intra-
cellular viral DNA [28,29]. More recently, IFI16 has
been reported as a key player in inducing pyroptosis in
abortively infected quiescent CD4+ T cells, thereby con-
tributing to the massive depletion of CD4+ T cells ob-
served during HIV infection [30,31]. Accumulating
evidence suggest that restriction factors, such as TRIM5α
[32] and BST2/tetherin [33-35] may also act as immune
sensors and direct anti-HIV effects of IFI16 warrant fur-
ther study. Conversely, some genes that displayed anti-
HIV activity are known to be involved in signaling, both in
various cancers (CD164, TNFRSF10A/D, ZWINT, MT1X,
IL3) and immune or T cell activation (GBP5, CD1A).
Thus, these genes may not inhibit HIV-1 directly but
could also induce cellular responses associated with the
expression of other innate immunity factors. This possibil-
ity is in agreement with our observation that some candi-
date factors inhibited various viral promoters. It is also
noteworthy, however, that 293T cells lack many intact
immune signaling pathways and did not express detect-
able levels of interferon after transfection with constructs
expressing the various candidate factors. Further studies
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indirect anti-HIV effects.
Two of the 27 cellular genes examined (SP110 and
IL1A) enhanced production of infectious HIV-1. SP110
is part of a leukocyte-specific nuclear body component
that may also play a role in the regulation of gene tran-
scription. Mutations in SP110 are associated with im-
munodeficiency [36]. It has been reported that this
factor stabilizes EBV mRNAs and enhances lytic viral
gene expression [37]. The strongest enhancing effects on
infectious virus production (up to 7-fold in dose-
dependency studies) were observed for IL1A. This cyto-
kine plays a key role in inflammation and the regulation
of the immune response. It has been reported that HIV-
1-exposed seronegative sex workers show reduced levels
of IL1A expression in their genital mucosa [38]. Thus,
the present results confirm and expand previous data
supporting that these cellular factors may enhance viral
infection and clearly warrant further investigation.
In most cases, the effect of the candidate restriction
genes in the FACS-based assays, intra- and extracellular
p24 levels and infectious virus production correlated
with one another, suggesting that reduced viral gene ex-
pression and/or translation are responsible for the in-
hibitory activity of the cellular factors rather than effects
on virus release or virion infectivity. In support of this,
preliminary data using LTR-luciferase reporter con-
structs suggest that many candidates suppress LTR
activity (Figure 5). Nonetheless, our results also provide
evidence that some candidate genes target different steps
of the viral life cycle. For example, the guanylate-binding
protein 5 (GBP5) and the mucin-like factor SPN (also
known as leukosialin, sialophorin or CD43) reduced viral
infectivity more severely than the levels of cell-free p24
antigen and may thus specifically reduce virion
infectivity. GBP5 is a member of the dynamin superfam-
ily of GTPases, which have been implicated in protection
against various pathogens [39,40]. Another factor
(IFITM3), that was identified by our screen and reduced
infectious virus production, was recently shown to be
incorporated into HIV-1 virions and to impair their
infectiousness [41,42]. SPN regulates CD4+ T cell prolif-
eration and migration and shows reduced expression
and aberrant glycosylation in HIV-1-infected individuals
[43,44]. Thus, it is conceivable that GBP5, SPN and
IFITM3 may affect virion infectivity although the under-
lying molecular mechanisms of the former two remain
to be determined.
Some known host restriction factors, i.e. APOBEC3G,
Tetherin and SAMHD1, were initially discovered be-
cause they are counteracted by viral accessory proteins
[4,5]. We found that the absence of intact vpr, vpu and
nef genes increased the inhibitory effects of several can-
didate factors (e.g. APOL1, APOL6, CD164, GBP5, SPN,CD3E, ZWINT and PIP) on p24 and infectious virus pro-
duction. However, the differences were generally modest
because even wt HIV-1 was efficiently inhibited at high
expression levels of the candidates. Notably, over-
expression of known restriction factors, such as tetherin,
can also overcome the viral antagonists. Thus, it remains
to be clarified whether the lower intrinsic infectiousness
of the Δ3 HIV-1 construct compared to the wt virus or
specific antagonistic effects of the accessory Vpr, Vpu
and/or Nef are responsible for the observed differences
in susceptibility to inhibition by some candidate factors.
Not all recognized restriction factors would have been
identified under the criteria of the evolutionary genetic
screen because of the criteria that imposed a dN/dS > 1.
We could however demonstrate that alternative ap-
proaches that model several characteristics of innate im-
munity genes ranked all known restriction factors and
most of the novel candidates among the top 5% genes in
the genome. Overall, genes that emerged from the screen
were strongly induced by interferon alpha. These results
indicate that they are bona fide interferon-stimulated genes
(ISGs) that are possibly endowed with antiviral activity.
Our ongoing studies aim to further define the antiviral
mechanisms of the most potent and specific candidate
genes as well as their possible interaction with the
accessory viral proteins.
In summary, we show that the number of cellular
genes showing evolutionary and functional characteris-
tics similar to known host restriction factors is limited.
Interferon treatment induced expression of most of
these genes in CD4+ T cells and over-expression of a
strikingly high proportion of them in transfected 293T
cells inhibited the production of infectious HIV-1. These
results are consistent with the observation that inter-
feron administration, likely through the action of yet to
be characterized interferon stimulated genes, inhibits
HIV and related primate lentiviruses [45,46]. The under-
lying mechanisms and the relevance of these potential re-
striction factors to the control of HIV-1 replication in
relevant viral target cells and in vivo remain elusive and
further characterization of these genes may improve our
understanding of cellular defense mechanisms.
Experimental Procedures
Expression and protein interaction datasets
We used transcriptome data from purified CD4+ T cells
from 128 HIV-1 infected seroconverting individuals repre-
senting the complete range of viral setpoint [3] using Illu-
mina Human HT-12 V3 BeadChip arrays (Illumina).
Patient spVL was calculated as the average of all log10
transformed viral load measurements (RNA copies/ml)
after the acute phase of infection and prior to disease pro-
gression (CD4 < 350 cells/ml) or the initiation of ART as
described [47].
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sion level of each gene on patient spVL controlling for
gender, age, CD4+ T cell viability and batch effect. In
addition, we compiled data from transcriptome analysis
of other active infections that used comparable genome-
wide technologies (Illumina, Affymetrix and other arrays
containing >20,000 human transcripts): the transcrip-
tome of lymph nodes of HIV-infected individuals [8],
and expression analyses of peripheral blood from indi-
viduals with tuberculosis [9], typhoid fever [10], and
dengue [11,12]. Based on the HIV host transcriptome
studies, we defined post-hoc a HIV-1 expressed gene set
that included 527 genes upregulated during in vivo infec-
tion. The NCBI HIV-1-human protein interaction database
(www.ncbi.nlm.nih.gov/RefSeq/ HIVInteractions/) and the
“global landscape of HIV-human protein complexes” [15]
were used to evaluate interactions between HIV-1 and
cellular factors. InnateDB (www.innatedb.ca), a publicly
available database of the genes, proteins, experimentally-
verified interactions and signaling pathways involved in
the innate immune response was included to evaluate the
general profile of genes participating in the response to
microbial infection. Genes were extracted from the
OMIM Gene Map (www.ncbi.nlm.nih.gov/sites/entrez?
db=omim), and a dedicated set was created by including
genes associated with a disease and C = confirmed -
observed in at least two laboratories or in several families.
Codon alignments of primate orthologous genes
Genome-wide codon alignments of orthologous genes for
up to nine simian and prosimian species (human, chim-
panzee, gorilla, orangutan, macaque, marmoset, tarsier,
bushbaby, and mouse lemur) were collected from
Ensembl v57. First, one-to-one orthologous primate gene
trees were gathered from the Ensembl Compara database
by extracting the sub-tree corresponding to all ‘one2one’
primate orthologs of each human gene, as annotated by
Compara’s gene tree reconciliation and homology annota-
tion method [48]. These one-to-one primate gene trees,
which included branch lengths in units of expected nu-
cleotide substitutions per site, were used to guide the rest
of the analysis.
It has been shown that errors in sequencing, annota-
tion and alignment can lead to excessive false positives
in downstream evolutionary analyses [49]. As a result,
efforts were made to avoid including possibly erroneously
sequenced or aligned bases in our dataset. Comparison
between Compara’s protein-based alignments and its
DNA-based alignments showed that the protein-based
alignments often contained missing or alternatively-
spliced exons in otherwise highly similar primate ortho-
logs, leading to stretches of erroneously-aligned bases
and inflated estimates of evolutionary rates and dN/dS
(data not shown). In order to avoid such errors, wegathered human-flattened genomic alignments by using
exon coordinates from the human Consensus Coding
Sequence (CCDS) transcript, or if no CCDS transcript
was available, the longest human protein-coding tran-
script, to extract all available aligned primate DNA
sequences from the ‘12 eutherian mammals’ DNA-
based multiple genomic alignments from Ensembl's
Enredo-Pecan-Ortheus pipeline [50]. Low-quality gen-
omic sequence was excluded by masking any nucleo-
tides with a PHRED (or PHRED-equivalent) quality
score below 30 (corresponding to an error rate of 1 in
1,000) from the chimpanzee, orangutan, macaque, mar-
moset, tarsier, bushbaby and mouse lemur source
genomes with ‘N’ characters; genome quality scores
were downloaded from the originating institutions for
each genome assembly used in Ensembl v57. Finally,
sequences in the generated alignments were cleaned in
preparation for codon model analysis by masking out
any frameshifting indels (which within these closely-
related primates are more likely to be the result of
sequencing error than true biological indels) and pre-
mature stop codons with ‘N’ characters. The precision
of the genome-wide values of dN/dS was assessed by
contrasting the estimates with those from 126 curated
alignments [17].
The codeml program from PAML v4.4 was used to
evaluate each alignment for evidence of positive selec-
tion acting on one or more amino acid sites throughout
the evolutionary tree of primates. Specifically, we first
used codeml model M0 to infer branch lengths for the
evolutionary tree corresponding to each alignment, and
then we used those branch lengths as input to models M7
and M8 in order to perform a likelihood ratio test (LRT)
for evidence of localized positive selection [51]. P-values
were calculated by comparing the LRT statistic to the chi-
squared distribution with 2 degrees of freedom, and the
set of raw p-values was corrected for multiple testing
using the Benjamini-Hochberg method [52]. The ad-
justed p-value for a given alignment represents the
overall expected false discovery rate when using that
alignment's LRT statistic as a cutoff threshold. Raw and
adjusted p-values for the candidate genes are included
in Table S1.Statistics
The analysis of the differences in distributions used per-
mutation test (n = 100,000) with Kolmogorov-Smirnov
statistics. Probability density functions for the various
gene sets (Figure 1) were plotted assuming continuous
dN/dS values using kernel density estimates. Statistical
analyses and graphical representations were performed
by using the R package (www.r-project.org). Correlation
analysis was performed using Pearson r evaluation.
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Bi-cistronic pCG expression vectors containing the im-
mediate early promoter of human cytomegalovirus
(CMV) coexpressing a candidate gene and BFP via an
internal ribosome entry site (IRES) were generated as
described elsewhere [53,54]. Briefly, the candidates were
amplified from human cDNA obtained from primary
blood cells by standard PCR reaction using primers
introducing flanking XbaI and MluI restriction sites for
cloning into the expression vector. All PCR-derived in-
serts were sequenced to confirm their accuracy. Silent
mutations were accepted.
Proviral HIV-1 constructs
Generation of wt HIV-1 (NL4-3-based) proviral reporter
constructs containing a functional nef gene followed by an
IRES and the eGFP gene and the triple mutant (ΔvpuΔ-
nefΔvpr) have been described previously [19,54,55].
Cells and transfection
HEK293T cells were maintained in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% FCS
(1% Glutamine, 1% Penicillin/Streptomycin). A total of
500,000 293T cells per well were seeded in 6-well plates
and transfected with 5 μg DNA (1:1 ratio provirus:candi-
date gene) at a confluence of about 70% by the calcium
phosphate method. TZM-bl cells were kindly provided
by Drs. Kappes and Wu and Tranzyme Inc. through the
NIH AIDS Reagent Program and were kept in DMEM
supplemented with 10% FCS (1% Glutamine and 1%
Penicillin/Streptomycin). TZM-bl cells express large
amounts of CD4, CCR5 and CXCR4 and contain the β-
galactosidase gene under the control of the HIV-1
promoter.
Infectivity assay
The yield of infectious HIV-1 was determined by a 96-
well infection assay using TZM-bl indicator cells. Briefly,
6,000 cells were seeded out in 96-well dishes in a volume
of 100 μl and infected in triplicate after overnight incu-
bation with 10 or 100 μl of virus stocks. Three days later
infection was detected using a galactosidase screen kit
from Applied Bioscience as recommended by the manu-
facturer. β-Galactosidase activities were quantified as
relative light units per second (RLU/s) using an Orion II
Microplate Luminometer (Berthold).
p24 antigen ELISA
Nunc immuno maxi sorb surface 96-well plates were
coated with a mouse anti-p24 monoclonal (MAK183)
antibody (EXBIO) overnight. After blocking, Triton X-
100 lysed supernatants or cells were transferred to
the 96-well plates. The next day, plates were washed
and incubated with a polyclonal rabbit anti-HIV-1p24 antibody (Eurogentec) for 1 h. Next, plates were
washed and incubated with a goat anti-rabbit antibody
conjugated with horseradish peroxidase (Dianova, 111-
035-008) followed by the addition of TMB peroxidase sub-
strate. The reaction was stopped with 0.5 M H2SO4 and
OD was measured at 450/650 nm.Flow cytometric analysis
Flow cytometry analysis of BFP and eGFP reporter ex-
pression in 293T cells transfected with bi-cistronic vec-
tors coexpressing the gene candidate and BFP together
with proviral HIV-1 IRES eGFP was performed on a
FACS CANTO II (BD) flow cytometer essentially as de-
scribed previously [54]. For analysis, the percentage of
BFP/eGFP double positive cells was determined in rela-
tion to BFP positive cells in total. All values were nor-
malized to the sample transfected with a control plasmid
coding for no functional protein followed by an IRES
BFP cassette.Cytotoxicity assay
The potential cytotoxicity of candidate genes was
evaluated by MTT assay. 293T cells (n=20,000) were
transfected in 96-well format with vectors expressing the
candidate genes. After 2 days 10 μl of a 5 mg/ml MTT
(3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium
bromide, Sigma #M2003) solution were added and incu-
bated for three hours. Thereafter cell free supernatant
was discarded, formazan crystals were solubilized in
100 μl DMSO-Ethanol (1:1) and OD was detected at
490/650 nm to evaluate cell viability.Promoter reporter assays
To determine the modulation of viral promoter activity,
293T cells were cotransfected with equal amounts
(2.5 µg) of firefly luciferase reporter vectors for the HIV-1
long terminal repeat (LTR), HSV thymidine kinase (TK)
and CMV immediate early (IE) promoters as well as vec-
tors coexpressing the candidate genes and BFP. The HIV-
1 LTR promoter was activated by cotransfection of a
plasmid (0.5 µg) expressing HIV-1 NL4-3 Tat if indicated.
40 h post transfection, cells were lysed in Luciferase Cell
Culture Lysis Reagent (Promega, E1531) and firefly lucif-
erase activity was determined using the Promega Lucifer-
ase Assay System (E1501) according to the manufacturer’s
protocol. The pCMV-IE and pHSV-TK red firefly lucifer-
ase reporter vectors were purchased from Thermo Scien-
tific (16156 and 16157, respectively). The 5’-LTR of HIV-1
NL4-3 was inserted into the pGL3 enhancer vector from
Promega (E1771) via XhoI/MluI. HIV-1 NL4-3 Tat was
cloned into a pCG expression vector via XbaI/MluI.
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Resting CD4+ T cells were purified from two healthy
blood donors by Ficoll gradient separation followed by
negative selection and magnetic separation using the hu-
man CD4+ T Cell enrichment kit supplemented with
anti-HLA-DR, anti-CD25 and anti-CD69 (Stem Cell
Technologies). Cells (106) were incubated for 24 hours,
either with medium only, or with 100 or 1000 IU/ml
interferon α (Roferon-A, Roche) or interferon γ (R&D
Systems), or with 2 μg anti-CD3/1 μg anti-CD28 and
100 U/ml recombinant interleukin-2 (R&D Systems) to
mimic TCR stimulation. After 24 hour incubation, total
RNA extraction was performed using Illustra RNAspin
mini isolation kit (GE Healthcare) and further processed
for mRNA-Seq library preparation (TruSeq RNA sample
prep kit, Illumina). 100 bp paired-end sequencing was
performed using Illumina HiSeq2000. About 140 mio
read pairs were obtained for the samples. Sequencing
reads were quality filtered before alignment using Cuta-
dapt [56] and PrInseq [57]. Cleaned sequencing reads
were aligned to a build genome using SOAPsplice. Gene
expression was assessed by determining the number of
mapped reads per gene using HTSeq-count tool,
followed by DESeq R package normalization. An add-
itional normalization step taking into account the gene
coding length was performed so that the resulting
counts could be compared across samples for a given
gene, and also between genes.Ranking screen
A set of 15,052 protein-coding genes was annotated with
nine parameters informative for response to HIV-1 infec-
tion or evolutionary history. Parameters included in vivo
response to HIV-1 infection (i.e. expression correlation
with viral load [3], primate dN/dS value, codon-specific
positive selection (PAML), measurements of cross species
adaptive evolution (the McDonald-Kreitman value com-
paring human sequence to chimp, orangutan or rhesus
[58], burden of synonymous, missense and non-sense vari-
ation, intolerance to functional variation (rare variant in-
tolerance score obtained from [59]) and number of
paralogs. Burden of synonymous, missense and non-sense
variation was taken from exome sequence data on ~6,300
individuals sequenced as part of the NHLBI exome se-
quencing project (http://evs.gs.washington.edu/EVS/).
Burden was calculated per gene as the total number of
variants in each class divided by gene length. Genes were
ranked for each parameter (with top ranked genes show-
ing high positive correlation with HIV viral load and high
levels of within and between species diversity) and the
ranks were summed giving equal weight to each measure-
ment. Beginning with all measurements, parameters were
iteratively dropped and re-included (individually and incombination) in the ranking and the final model was se-
lected based on the set of parameters that optimized the
ranking of known HIV-1 restriction factors. The final set
of parameters included in vivo response to HIV-1 infec-
tion, dN/dS value and evidence for codon-specific positive
selection (PAML P-value).Additional files
Additional file 1: Table S1. Genes selected on the basis of
evolutionary history in primates, expression during HIV-1 infection
in vivo, or issued from the HIV-1 interaction database. Because of errors
in sequencing, annotation and alignment can lead to excessive false
positives in downstream evolutionary analyses. Therefore, we
assessed dN/dS estimates using both Ensembl Compara’s
protein-based alignments (columns c_m0 and c_m), and DNA-based
alignments of primate sequences generated from genomic DNA
alignments (column g_m0). The “m0” columns (c_m0 and g_m0)
show gene-wide dN/dS values estimated using the SLR software
under a one-ratio model (i.e. one dN/dS value per gene), while the
“m” column (c_m) shows the mean across the gene of all
codon-specific dN/dS estimates using SLR's sitewise model
(Massingham and Goldman, 2005). The raw and adjusted p-values for
sitewise positive selection, measured using the so-called 'site' test for
positive selection (Yang, 2007), are included (column paml_pval, and
Benjamini-Hochberg FDR-adjusted: paml_adj_pval). In column
“Association”, E=differentially expressed during HIV-1 infection in vivo,
I= included in the NCBI HIV-1. interaction database. The effect of the
candidate genes on NL4-3 and D3 HIV-1 is indicated in the
following columns. Each value represents the average values (n≥3)
obtained in the presence of one of the 27 individual candidates
analyzed.
Additional file 2: Figure S1. Assessment of possible cytotoxic effects of
candidate genes. 293T cells were transfected with 2.5 µg of constructs
expressing the candidate genes and the cell viability was examined
two days later by MTT assay. Lack of cytotoxicity was confirmed in the
CellTiter-Glo® Luminescent Cell Viability Assay. All data were
normalized to the BFP only control construct (100%) and are
presented as mean ±SD (n = 3). Figure S2. Assessment of
antiviral effects of candidate genes. Impact of individual candidate
factors on HIV-1 gene expression, release and infectivity. Candidates
were ranked from the left to the right based on their inhibitory effect
on the production of infectious wt HIV‑1 (blue). Results obtained for
the D3 virus (red) are shown for comparison. The detection limit for
CA and CF p24 antigen in the ELISA assay is about 0.5%. Figure S3.
Correlation between the effect of the candidate genes on wt and D3
HIV-1 gene expression, virus release and viral infectivity. (A) Correlation
between the effect of the candidate genes on wt and D3 HIV-1 in the
indicated assays. Each symbol represents the average values (n≥3) obtained in
the presence of one of the 28 individual candidate genes analyzed. Candidate
genes that reduced the values for both wt and D3 virus below 50% (FACS-
based assays) or below 10% (p24 expression and infectious virus production)
are color coded green; those that achieved this only for the D3 construct
yellow; and enhancers of both viruses red. (B) Correlation between the effects
of the candidate genes in the different assays for viral gene expression, p24
antigen production and viral infectivity. The upper panels give the results
obtained for the wt HIV-1 construct and the lower panel provides the data
generated using the D3 mutant construct.
Additional file 3: Table S2. Ranking of candidates in a relaxed
screen. A set of 15,052 protein-coding genes was annotated with nine
parameters informative for response to HIV-1 infection or evolutionary
history. Parameters included in vivo response to HIV-1 infection, dNdS
value, codon-specific positive selection, measurements of cross species
adaptive evolution, burden of synonymous, missense and non-sense
variation, intolerance to functional variation and number of paralogs. We
highlight in yellow genes selected in the main screen, and in blue,
pardigmatic restriction factors.
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